Status:
UNKNOWN
Cyclin D1 as a Prognostic Factor in Multiple Myeloma and Its Association With the Immunological Prognostic Factor PDL1 and Clinical and Biochemical Lab Tests
Lead Sponsor:
Sohag University
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Multiple myeloma (MM) is the most common bone marrow malignancy of terminally differentiated plasma cells. It accounts for about 1% of all malignant diseases and 10% of haematological malignancies and...
Eligibility Criteria
Inclusion
- Patients older than 18 year with newly diagnosed MM.
- Approval to sign an informed written consent.
Exclusion
- 1\. Patient younger than 18 years. 2.Refusal to sign an informed written consent.
Key Trial Info
Start Date :
September 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05995808
Start Date
September 1 2023
End Date
August 1 2025
Last Update
August 16 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.